Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

PHASE4TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

September 30, 2015

Conditions
ProteinuriaTransplant Glomerulopathy
Interventions
DRUG

Acthar

Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.

Trial Locations (1)

60612

University of Illinois at Chicago, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

University of Illinois at Chicago

OTHER